Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Legend Biotech Corporation, Relay Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Legend Biotech Corporation, Relay Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Legend Biotech Corporation, Relay Therapeutics and Inc.

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and Legend Biotech Corporation, Relay Therapeutics, Inc. Stock News

As of April 30, 2026, Legend Biotech Corporation had a $4.3 billion market capitalization, compared to the Biotechnology median of $276.3 million. Legend Biotech Corporation’s stock is up 6.6% in 2026, down 3.1% in the previous five trading days and down 31.69% in the past year.

Currently, Legend Biotech Corporation does not have a price-earnings ratio. Legend Biotech Corporation’s trailing 12-month revenue is $1.0 billion with a -28.8% net profit margin. Year-over-year quarterly sales growth most recently was 64.2%. There are no analysts providing consensus earnings estimates for the current fiscal year. Legend Biotech Corporation does not currently pay a dividend.

As of April 30, 2026, Relay Therapeutics, Inc. had a $2.5 billion market cap, putting it in the 57th percentile of all stocks. Relay Therapeutics, Inc.’s stock is up 53.1% in 2026, down 14.4% in the previous five trading days and up 318.07% in the past year.

Currently, Relay Therapeutics, Inc. does not have a price-earnings ratio. Relay Therapeutics, Inc.’s trailing 12-month revenue is $15.4 million with a % net profit margin. As of April 30, 2026, Relay Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-1.522 per share for the current fiscal year. Relay Therapeutics, Inc. does not currently pay a dividend.

How We Compare Legend Biotech Corporation, Relay Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Legend Biotech Corporation, Relay Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Legend Biotech Corporation, Relay Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Legend Biotech Corporation	LEGN	F
Relay Therapeutics, Inc.	RLAY	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Legend Biotech Corporation has a Value Score of 19, which is Ultra Expensive. Relay Therapeutics, Inc. has a Value Score of 8, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Legend Biotech Corporation, Relay Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Legend Biotech Corporation, Relay Therapeutics or Inc. is the better investment when it comes to value.

Legend Biotech Corporation, Relay Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Legend Biotech Corporation	LEGN	F
Relay Therapeutics, Inc.	RLAY	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Legend Biotech Corporation has a Growth Score of 18, which is Very Weak. Relay Therapeutics, Inc. has a Growth Score of 3, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Legend Biotech Corporation, Relay Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Legend Biotech Corporation, Relay Therapeutics or Inc. is the better investment when it comes to sustainable growth.

Legend Biotech Corporation, Relay Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Legend Biotech Corporation	LEGN	C
Relay Therapeutics, Inc.	RLAY	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Legend Biotech Corporation has a Momentum Score of 47, which is Average. Relay Therapeutics, Inc. has a Momentum Score of 97, which is Very Strong.

The Momentum Grade Winner: Relay Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Relay Therapeutics, Inc. is considered to have stronger momentum compared to Legend Biotech Corporation. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Relay Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Legend Biotech Corporation, Relay Therapeutics and Inc. Grades

In addition to Value, Momentum and Growth, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Legend Biotech Corporation, Relay Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Legend Biotech Corporation, Relay Therapeutics or Inc. Stock?

Overall, Legend Biotech Corporation stock has a Value Score of 19, Growth Score of 18 and Momentum Score of 47.

Relay Therapeutics, Inc. stock has a Value Score of 8, Growth Score of 3 and Momentum Score of 97.

Comparing Legend Biotech Corporation, Relay Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.